Kintz Samuel 4
4 · Enliven Therapeutics, Inc. · Filed Jul 21, 2025
Insider Transaction Report
Form 4
Kintz Samuel
DirectorPRESIDENT AND CEO
Transactions
- Sale
Common Stock
2025-07-17$22.69/sh−4,687$106,360→ 944,055 total(indirect: See footnote) - Sale
Common Stock
2025-07-17$21.58/sh−4,150$89,552→ 948,742 total(indirect: See footnote) - Sale
Common Stock
2025-07-17$23.37/sh−3,663$85,607→ 940,392 total(indirect: See footnote)
Footnotes (5)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
- [F2]This transaction was executed in multiple trades at prices ranging from $21.26 to $22.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.
- [F4]This transaction was executed in multiple trades at prices ranging from $22.28 to $23.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F5]This transaction was executed in multiple trades at prices ranging from $23.285 to $23.595. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.